X0609 4 2026-08-16 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001742485 Kumar Neil false C/O BRIDGEBIO PHARMA, INC. 3160 PORTER DR., SUITE 250 PALO ALTO CA 94304 1 1 0 0 Chief Executive Officer 0 Common Stock 2026-08-16 4 M 0 33544 A 276871 D Common Stock 2026-08-16 4 M 0 19599 A 296470 D Common Stock 2026-08-16 4 M 0 11554 A 308024 D Common Stock 2026-08-16 4 M 0 6520 A 314544 D Common Stock 2026-08-16 4 F 0 36237 79.86 D 278307 D Common Stock 515686 I By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Common Stock 3568447 I By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Common Stock 750000 I By NK 2026 GRAT Restricted Stock Units 2026-08-16 4 M 0 33544 0 D Common Stock 33544 67088 D Restricted Stock Units 2026-08-16 4 M 0 19599 0 D Common Stock 19599 117596 D Restricted Stock Units 2026-08-16 4 M 0 11554 0 D Common Stock 11554 115538 D Restricted Stock Units 2026-08-16 4 M 0 6520 0 D Common Stock 6520 91274 D Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 71,217 shares of Common Stock underlying the Reporting Person's RSUs. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Reflects a prior transfer of 750,000 shares of Common Stock from the Kumar Haldea Revocable Trust to the NK 2026 GRAT. The transfer constituted only a change in form of beneficial ownership and was exempt under Rule 16a-13 of the Securities Exchange Act of 1934, as amended. These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. /s/ Will Solis, Attorney-in-Fact 2026-08-18